Odyssey Thera Expands Pfizer Drug-Discovery Deal
Odyssey Thera said last week that it has expanded its agreement with Pfizer to profile compounds using Odyssey's panel of cell-based assays in order to characterize mechanism of action and pathway activity in human cells.
The project will focus on 500 compounds from multiple therapeutic areas, Odyssey said.
Odyssey Thera's cell-based drug-discovery platform is based on its patented protein-fragment complementation assay.
The companies began their collaboration in November 2003.